Clinical features, culprit drugs, and allergology workup in 41 cases of fixed drug eruption.
epidemiology
fixed drug eruption
oral rechallenge
patch test
Journal
Contact dermatitis
ISSN: 1600-0536
Titre abrégé: Contact Dermatitis
Pays: England
ID NLM: 7604950
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
06
02
2019
revised:
04
07
2019
accepted:
09
07
2019
pubmed:
11
7
2019
medline:
3
3
2020
entrez:
11
7
2019
Statut:
ppublish
Résumé
Fixed drug eruption (FDE) represents a drug-related cutaneous reaction. Many drugs been associated with this clinical entity, with continually evolving documentation of implicated agents and clinical presentations. A bullous form can occur although it is rare. To assess the epidemiological and clinical characteristics of FDE. We retrospectively analysed all FDE cases who presented to the Clinical Pharmacology Department at the University Hospital, Monastir, Tunisia, for allergy workup. The mean age of the 41 confirmed FDE cases was 43.8 ± 15.5 years. The time between first lesion onset and FDE diagnosis was less than 1 month for 13 patients (31.7%). Fifteen patients had bullous lesions. The upper limbs were the most common location (65.9% of cases). The patch tests were positive in 27 cases; a provocation test yielded a positive response in the four cases tested. Nonsteroidal anti-inflammatory drugs (NSAIDs) were involved in 51.2%, antibiotics in 24.4%, and other analgesics in 19.5%. The most common offending drug was mefenamic acid in 24.4% of cases. Bullous lesions were significantly associated with paracetamol intake (P = .014; odds ratio 16.7; 95% confidence interval: 1.76-158). NSAIDs and antibiotics were the most implicated in inducing FDE; paracetamol was associated with bullous lesions.
Sections du résumé
BACKGROUND
BACKGROUND
Fixed drug eruption (FDE) represents a drug-related cutaneous reaction. Many drugs been associated with this clinical entity, with continually evolving documentation of implicated agents and clinical presentations. A bullous form can occur although it is rare.
OBJECTIVES
OBJECTIVE
To assess the epidemiological and clinical characteristics of FDE.
METHODS
METHODS
We retrospectively analysed all FDE cases who presented to the Clinical Pharmacology Department at the University Hospital, Monastir, Tunisia, for allergy workup.
RESULTS
RESULTS
The mean age of the 41 confirmed FDE cases was 43.8 ± 15.5 years. The time between first lesion onset and FDE diagnosis was less than 1 month for 13 patients (31.7%). Fifteen patients had bullous lesions. The upper limbs were the most common location (65.9% of cases). The patch tests were positive in 27 cases; a provocation test yielded a positive response in the four cases tested. Nonsteroidal anti-inflammatory drugs (NSAIDs) were involved in 51.2%, antibiotics in 24.4%, and other analgesics in 19.5%. The most common offending drug was mefenamic acid in 24.4% of cases. Bullous lesions were significantly associated with paracetamol intake (P = .014; odds ratio 16.7; 95% confidence interval: 1.76-158).
CONCLUSIONS
CONCLUSIONS
NSAIDs and antibiotics were the most implicated in inducing FDE; paracetamol was associated with bullous lesions.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
336-340Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol. 1998;37:833-838.
Jung J-W, Cho S-H, Kim K-H, Min K-U, Kang H-R. Clinical features of fixed drug eruption at a tertiary Hospital in Korea. Allergy Asthma Immunol Res. 2014;6:415-420.
Nnoruka EN, Ikeh VO, Mbah AU. Fixed drug eruption in Nigeria. Int J Dermatol. 2006;45:1062-1065.
Pai VV, Kikkeri NN, Athanikar SB, Shukla P, Bhandari P, Rai V. Retrospective analysis of fixed drug eruptions among patients attending a tertiary care center in southern India. Indian J Dermatol Venereol Leprol. 2014;80:194.
Kavoussi H, Rezaei M, Derakhshandeh K, et al. Clinical features and drug characteristics of patients with generalized fixed drug eruption in the west of Iran (2005-2014). Dermatol Res Pract. 2015;236703.
Heng YK, Yew YW, Lim DSY, Lim YL. An update of fixed drug eruptions in Singapore. J Eur Acad Dermatol Venereol. 2015;29:1539-1544.
Cheng-Han L, Yi-ChunChen Y-TC, Chia-Ying C, Chia-Yu C. Fixed-drug eruption: a retrospective study in a single referral center in northern Taiwan. Dermatologica Sinica. 2012;30:11-15.
Brahimi N, Routier E, Raison-Peyron N, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol. 2010;20:461-464.
Andrade P, Brinca A, Gonçalo M. Patch testing in fixed drug eruptions--a 20-year review. Contact Dermatitis. 2011;65:195-201.
Gupta R. Drugs causing fixed drug eruptions: confirmed by provocation tests. Indian J Dermatol Venereol Leprol. 2003;69:120-121.
Özkaya-Bayazit E. Specific site involvement in fixed drug eruption. J Am Acad Dermatol. 2003;49:1003-1007.
Kauppinen K. Cutaneous reactions to drugs with special reference to severe bullous muco-cutaneous eruptions and sulphonamides. A clinical study. Acta Derm Venereol. 1972;52:89.
Kanwar AJ, Bharija SC, Singh M, Belhaj MS. Ninety-eight fixed drug eruptions with provocation tests. Dermatologica. 1988;177:274-279.
Rahman MH. Fixed drug eruption in Bangladeshi population: confirmed by provocative test. Int J Dermatol. 2014;53:255-258.
Lee AY. Topical provocation in 31 cases of fixed drug eruption: change of causative drugs in 10 years. Contact Dermatitis. 1998;38:258-260.
Chaabane A, Fredj NB, Chadly Z, Boughattas NA, Aouam K. Fixed drug eruption: a selective reaction to amoxicillin. Therapie. 2013;68:183-185.
de Argila D, Angeles Gonzalo M, Rovira I. Carbamazepine-induced fixed drug eruption. Allergy. 1997;52:1039.
Naima S, Rafik M, Hanene HK, et al. Fixed drug eruption caused by carbamazepine in a patient with lafora body disease. 2017;3.
Chadly Z, Aouam K, Chaabane A, Belhadjali H, Abderrazzak Boughattas N, Zili JE. A patch test confirmed phenobarbital-induced fixed drug eruption in a child. Iran J Allergy Asthma Immunol. 2014;13:214-217.